Randomized phase II trial of panitumumab, erlotinib, and gemcitabine (PGE) versus erlotinib-gemcitabine (GE) in patients with untreated, metastatic pancreatic adenocarcinoma.

被引：4
|
作者：
Kim, G. P.
Foster, N. R.
Salim, M.
Flynn, P. J.
Moore, D. F.
Zon, R.
Mowat, R. B.
Wiesenfeld, M.
McCullough, A. E.
Alberts, S. R.
机构：
[1] Mayo Clin, Jacksonville, FL 32224 USA
[2] North Cent Canc Treatment Grp, Rochester, MN USA
[3] Allan Blair Canc Ctr, Saskatoon, SK, Canada
[4] Metro Minnesota Community Clin Oncol Project, St Louis Pk, MN USA
[5] Wichita Community Clin Oncol Program, Wichita, KS USA
[6] Michiana Hematol Oncol PC, South Bend, IN USA
[7] Toledo Community Hosp, Oncol Program, Toledo, OH USA
[8] Oncol Associates Cedar Rapids, Cedar Rapids, IA USA
[9] Mayo Clin, Scottsdale, AZ USA
[10] Mayo Clin, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.4030
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4030
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Randomized phase II trial of panitumumab (P), erlotinib (E), and gemcitabine (G) versus erlotinib-gemcitabine in patients with untreated, metastatic pancreatic adenocarcinoma
    Kim, G. P.
    Foster, N. R.
    Salim, M.
    Flynn, P. J.
    Moore, D. F., Jr.
    Zon, R.
    Mowat, R. B.
    McCullough, A.
    Meyers, J. P.
    Alberts, S. R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [2] A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance)
    Halfdanarson, Thorvardur R.
    Foster, Nathan R.
    Kim, George P.
    Meyers, Jeffrey P.
    Smyrk, Thomas C.
    McCullough, Ann E.
    Ames, Matthew M.
    Jaffe, Jeffrry P.
    Alberts, Steven R.
    [J]. ONCOLOGIST, 2019, 24 (05): : 589 - +
  • [3] A randomized phase II clinical trial of gemcitabine, oxaliplatin, erlotinib combination chemotherapy versus gemcitabine and erlotinib in previously untreated patients with locally advanced or metastatic pancreatic cancer.
    Lim, Sung Hee
    Yun, Jina
    Lee, Min-Young
    Kim, Han Jo
    Kim, Kyoung Ha
    Kim, Se Hyung
    Lee, Sang-Cheol
    Bae, Sang Byung
    Kim, Chan Kyu
    Lee, Namsu
    Lee, Kyu Taek
    Park, Sung Kyu
    Hong, Dae Sik
    Choi, Hyun Jong
    Moon, Jong Ho
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [4] Phase II trial of neoadjuvant gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy in resectable pancreatic adenocarcinoma. A GEMCAD 10-03 trial
    Laquente, B.
    Conill, C.
    Fabregat, J.
    Cambray, M.
    Ayuso, J. R.
    Valls, C.
    Bombi, J. A.
    Serrano, T.
    Ferrandez, A.
    Poves, I.
    Sabater, L.
    Montagut, C.
    Rosello, S.
    Martin-Richard, M.
    Diaz-Beveridge, R.
    Rodriguez, J.
    Gallego, R.
    Garcia-Albeniz, X.
    Fernandez-Cruz, L.
    Maurel, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S416 - S416
  • [5] Phase I randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib as first-line treatment in patients with metastatic pancreatic cancer (SWOG-0727).
    Philip, Philip Agop
    Goldman, Bryan H.
    Ramanathan, Ramesh K.
    Lenz, Heinz-Josef
    Lowy, Andrew M.
    Whitehead, Robert P.
    Iqbal, Syma
    Gaur, Rakesh
    Benedetti, Jacqueline K.
    Blanke, C. D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [6] A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced or metastatic pancreatic adenocarcinoma
    Jo, Jung Hyun
    Jung, Dawoon E.
    Lee, Hee Seung
    Park, Soo Been
    Chung, Moon Jae
    Park, Jeong Youp
    Bang, Seungmin
    Park, Seung Woo
    Cho, Sangsook
    Song, Si Young
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2022, 151 (09) : 1565 - 1577
  • [7] A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer
    Oh, D.
    Lee, K.
    Lee, K.
    Sohn, C.
    Zang, D.
    Ryoo, H.
    Song, H.
    Kim, J.
    Bang, Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] Gemcitabine and Erlotinib with or without Oxaliplatin in Previously Untreated Advanced Pancreatic Cancer: A Randomized Phase II Trial
    Lim, Sung Hee
    Yun, Jina
    Lee, Min-Young
    Kim, Han Jo
    Kim, Kyoung Ha
    Kim, Se Hyung
    Lee, Sang-Chul
    Bae, Sang Byung
    Kim, Chan Kyu
    Lee, Namsu
    Lee, Kyu Taek
    Park, Seong Kyu
    Lee, Yun Nah
    Moon, Jong Ho
    [J]. YONSEI MEDICAL JOURNAL, 2021, 62 (08) : 671 - 678
  • [9] NCCTG phase II trial of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma.
    Kim, G. P.
    Oberg, A.
    Kabat, B.
    Sing, A.
    Hedrick, E.
    Campbell, D.
    Alberts, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 206S - 206S
  • [10] Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
    Van Cutsem, Eric
    Vervenne, Walter L.
    Bennouna, Jaafar
    Humblet, Yves
    Gill, Sharlene
    Van Laethem, Jean-Luc
    Verslype, Chris
    Scheithauer, Werner
    Cosaert, Aijing Shang Jan
    Moore, Malcolm J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (13) : 2231 - 2237
12345